导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.43% | 1402/4765 |
| 近一周 | -1.94% | 3152/5455 |
| 近一月 | -3.09% | 2159/5411 |
| 近一季 | -2.90% | 1506/5221 |
| 近半年 | 3.35% | 934/4910 |
| 近一年 | 8.94% | 1254/4390 |
| 近两年 | 54.48% | 1380/2953 |
| 近三年 | 34.24% | 933/2252 |
| 成立以来 | 64.84% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.53% 2815/4961 |
12.59% 2152/5312 |
- - |
- - |
| 2025 | 22.44% 1971/4813 |
1.38% 1638/3635 |
2.71% 1408/4076 |
14.19% 2939/4524 |
2.98% 795/4813 |
| 2024 | 15.01% 976/3463 |
3.78% 514/2808 |
-1.14% 947/3014 |
15.69% 1652/3129 |
-3.10% 2263/3463 |
| 2023 | -11.55% 1410/2656 |
4.18% 1025/2280 |
-3.78% 897/2385 |
-3.94% 1018/2515 |
-8.14% 2254/2655 |
| 2022 | -16.99% 541/2207 |
-10.78% 422/1919 |
7.29% 498/2016 |
-14.10% 1022/2113 |
0.95% 1422/2208 |
| 2021 | 4.22% 587/1822 |
-0.22% 342/1255 |
8.44% 622/1330 |
-4.07% 678/1466 |
0.40% 1122/1822 |
| 2020 | 41.77% 282/1250 |
-7.63% 558/1028 |
14.27% 559/1067 |
17.36% 106/1164 |
14.45% 274/1184 |
| 2019 | - - |
- - |
- - |
0.15% 553/850 |
6.95% 510/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 国投瑞银沪深300指数量化增强A VS. 长安沪深300非周期A(740101) |